

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
Atkinson et al.
INTERNATIONAL APPLICATION NO: EP 98/07792
FILED: December 1, 1998
U.S. APPLICATION NO: TBA
35 USC §371 DATE: May 22, 2000
FOR: PROTEINASE INHIBITOR FUSION PROTEINS

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application ep 98/07792, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in cursive script, reading "J. Timothy Meigs", written over a horizontal line.

J. Timothy Meigs
Attorney for Applicant
Reg. No. 38,241

Novartis Agribusiness Biotechnology Research Inc.
Patent Department
P.O. Box 12257
Research Triangle Park, NC 27709-2257
(919) 541-8587

Date: May 22, 2000